IL-2 Receptor (IL-2R) Alpha, Beta, and Gamma Chains Expressed on Blasts of Acute Myelocytic Leukemia May Not Be Functional
Preliminary clinical studies including IL-2 in chemotherapeutic strategies for treatment of acute myelocytic leukemia suggest that IL-2 may improve the overall outcome of the patients [1, 2]. To date, the mechanisms of eradication of blast cells are still unclear. Cytotoxic T and NK cells or secondary cytokines released after administration of IL-2 have been discussed to contribute to the elimination of leukemic cells [3–5]. However, it is important to know, whether IL-2 may directly influence AML blasts . In initial sudies, using flow cytometry, we found expression of considerable levels of the IL-2R alpha chain on blast cells in a low proportion of patients with AML. However, the IL-2R beta chain was more frequently expressed ranging from 0% to 98%. To confirm these results on a transcriptional level, we studied the expression of RNA of the IL-2R α, β, and γ chains by RT PCR in the bone marrow of 39 newly diagnosed patients with AML and in three AML derived cell lines. RNA for all three IL-2R chains was expressed in lines KG1, HEL 92.1.7 and K562. Surface expression of the IL-2R β chain was observed in all three lines, but of the α chain only in KG1 cells. In comparison with unstimulated cell lines incubation of the three lines with various amounts of IL-2 over 3 and 14 days did not influence their growth, measured by cell numbers and 3H-thymidin incorporation. RNA for the α chain was detectable in 12/39 patients, of the β chain in 10/39 patients and the γ chain in 29/39 patients with AML. Altogether the data suggest that the IL-2R expressed on AML blast cells may be incomplete and not functional. In future studies, functional properties of IL-2 R on blast cells obtained from newly diagnosed patients with AML will have to be investigated.
KeywordsCellulose Leukemia Agarose Bromide Chloroform
Unable to display preview. Download preview PDF.
- 2.Bergmann L, Heil G, Kolbe K, Lengfelder E, Brücher J, Lohmeyer J, Mitrou PS, Hoelzer D: Interleukin 2 (IL-2) is a feasible consolidation treatment and may prolong second complete remission (CR) of acute myelocytic leukemia. Ann Hematol 67 (1993) A9.Google Scholar
- 5.Foa R, Guarini A, Tos GA, Cardena S, Fierro MT, Meloni T, Tosto S, Mandelli F, Gavosto F: Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia treated with interleukin 2: Evidence for in vivo lymphokine-activated killer cell generation. Cancer Res 51 (1991) 964–968.PubMedGoogle Scholar
- 6.Foa R, Carretto P, Fierro MT, Bonferroni M, Cardena S, Guarini A, Lista P, Pegoraro L, Mandello F, Forni G, Gavosto F: Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukemia cells of myeloid and lymphoid origin. Brit J Haematol 75 (1990) 34–40.CrossRefGoogle Scholar
- 15.Aliléche A, Plaisance S, Han DS, Jasmin C, Azzarone B: In human melanoma cells interleukin 2 down modulates the surface expression of histocompatibility antigens class I and class II. Proc Am Assoc Cancer Res 33 (1992) 415.Google Scholar
- 20.Jahn B, Bergmann L, Fenchel K, Weidmann E, Schwulera U, Mitrou PS: CD3+CD4+ T cells as effective cells of autologous blast specific cytotoxicity in acute myelocytic leukemia. Ann Hematol 65, suppl. (1992) A122.Google Scholar